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Abstract
Background: Non-adherence to immunosuppressive therapy is a prevalent risk factor for poor clinical and after
kidney transplantation (KT), and has contributed to the lack of improvement in long-term graft survival over the
past decade. Understanding the multilevel correlates and risk factors of non-adherence is crucial to determine the
optimal level for planning interventions, namely at the patient, health care provider, KT centre, and health care
system level. Brazil, having the largest public transplantation program in the world and with regional differences
regarding access to health services and service implementation, is in a unique position to study this multilevel
approach. Therefore, the Adhere Brazil Study (ADHERE BRAZIL) was designed to assess the prevalence and
variability of non-adherence to immunosuppressants and to health behaviours among adult KT recipients in Brazil,
and to assess the multilevel correlates of non-adherence to immunosuppressive medication. We describe the
rationale, design, and methodology of the ADHERE BRAZIL study.
Methods/Design: This is an observational, cross-sectional, multicentre study that includes 20 Brazilian KT centres. A
stratified sampling approach is used, based on strata, with the following characteristics considered: geographical
region and transplant activity (number of KTs per year). A random sample of patients (proportional to the size of
the centre within each stratum) is selected from each centre. The prevalence of different health behaviours is
assessed through self-report. The assessment of multilevel correlates of non-adherence is guided by the ecological
model that considers factors at the level of the patient, health-care professional, and transplant centre, using
established instruments or instruments developed for this study. Data will be collected over an 18-month period,
with information obtained during the regular follow-up visits to the transplant outpatient clinic and directly entered
into the Research Electronic Data Capture (RedCap) system. Data entry is performed by a trained professional who
is part of the transplant team. The data collection began in December 2015.
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Discussion: This multicentre study is the first to evaluate multilevel correlates of non-adherence in KT patients and
will provide a reliable estimate of non-adherence in Brazilian KT patients.
Trial registration: ClinicalTrials.gov on 10/10/2013, NCT02066935.
Keywords: Patient adherence, Medication nonadherence, Immunosuppression, Health behaviour, Kidney
transplantation, Brazil, Design, Healthcare system,
Background
Kidney transplantation (KT) is the renal replacement
therapy that provides a better quality of life and lon-
ger survival [1, 2]. However, the long-term graft out-
come has not improved over the last decade, and
remains an important clinical problem [3, 4]. Non-
adherence to immunosuppressive therapy is a preva-
lent risk factor for this worse outcome in KT and
consequently contributes to the lack of improvement
in the long-term graft survival [5–7]. Assessing the
correlates and risk factors of non-adherence is cru-
cial to guide intervention development, i.e. interven-
tions needed at patient, health care providers, KT
centres or health care system level [5, 6, 8, 9].
The World Health Organization defines adherence as
a multidimensional process that involves factors related
to the following: socioeconomic profile (family income,
social support, cost of medications), the characteristics
of the disease and its treatment (comorbidities, chron-
icity of the disease, complexity of regimen), the patient
as an individual (self-efficacy, health beliefs, health liter-
acy), the health care professionals involved in the treat-
ment, and the health care system [10]. However, in
transplantation, as in other chronic diseases, most stud-
ies have focused only on the socioeconomic, disease-
and treatment-related factors [5, 8, 10, 11]. A meta-
analysis of 29,000 KT patients, performed in the modern
era of immunosuppressive therapy, reported that non-
adherence was explained only in part by the factors in-
cluded in the study. The authors suggested that other
factors, potentially linked to higher levels of care (i.e.
health care team organization and health care system),
also needed to be considered in order to understand pa-
tient non-adherence [11]. This view is reflected by the
ecological model shown in Fig. 1, which posits that a pa-
tient’s behaviour results from multilayered influences at
the level of the health care provider (micro), health care
organization (meso) and health care system and policies
(macro) [9, 12]. For instance, it has been shown that
practice patterns that apply better principles of chronic
illness management (CIM) are associated with
favourable clinical and health care utilization outcomes
in chronically ill populations [13]. Two studies had
found similar results in KT patients [14, 15]. KT can be
defined as a chronic disease as transplant patients are
dependent on lifelong therapy and follow-up. Moreover,
KT requires active patient participation in specific health
behaviours to improve outcomes, such as: medication tak-
ing, maintenance of regular physical activity, reduction/ces-
sation of alcohol intake, protection from ultraviolet sun,
cessation of smoking or maintenance of a non-smoking sta-
tus, and keeping medical appointments [16, 17].
To date, only one study has comprehensively ad-
dressed the multilevel factors associated with non-
adherence to immunosuppressive drugs among 1680
heart transplantation recipients, in 36 centres across 11
countries and 4 continents - The BRIGHT Study (Build-
ing Research Initiative Group: Chronic Illness Manage-
ment and Adherence in Transplantation). The BRIGHT
study also mapped practice patterns related to CIM in
heart transplantation [18, 19]. Such elaborate data is
lacking for KT and could contribute to identify lever-
aging points for adherence interventions.
Our group has recently evaluated selected multilevel
correlates in a single centre study involving patients after
the first year post-KT, in Brazil. Non-adherence to im-
munosuppressive therapy was identified in half of the
patients. Surprisingly, a better economic profile,
reflected by a higher family income, was the only vari-
able that correlated to non-adherence. Given the
Fig. 1 Ecological model used, adapted from Bronfenbrenner et al.,
[12] and Berben, [9] (with permission)
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inclusion of a single centre, meso level factors, such as
practice patterns during post-transplantation follow-up,
could not be evaluated [20].
Although non-adherence is a frequently reported behav-
iour in KT recipients, its prevalence varies according to
the method of diagnosis, operational definitions used, and
sampling method [5, 6, 11]. Adherence is defined as an
agreement between a patient’s behaviour and the pre-
scribed treatment, including the extent to which a patient
takes medications, follows a diet, and/or implements life-
style changes as prescribed by health care providers [10].
In transplantation, while studies have largely focused on
adherence to immunosuppressive therapy [21], less atten-
tion has been given to adherence to other health behav-
iours [11]. The prevalence of non-adherence to prescribed
immunosuppressive regimen among KT recipients ranges
between 19 and 25 cases per 100 patients per year (PPY)
[11]. Consequences of non-adherence are serious, includ-
ing more acute rejection episodes, worse graft function
and reduced survival, greater morbidity, and greater costs
to the health systems [5, 6, 8, 22–26]. In the absence of a
gold standard method to assess non-adherence to im-
munosuppressive therapy, a combination of methods is
preferred to maximize the sensitivity of the assessment
[27]. However, only a few studies have evaluated adher-
ence to immunosuppressive therapy applying this meth-
odology [20, 28, 29].
Adherence to other health behaviours after KT has
been much less studied. The prevalence of smoking
ranges from 2.8 to 4.0 PPY (median, 3.4 PPY) [11], and
has been associated with cardiovascular diseases and
higher mortality [30]. Less than two KT patients per 100
PPY are reported as not limiting/quitting alcohol con-
sumption [11], but it is not clear if alcohol consumption
is a risk factor for worse allograft and patient survival
[31, 32]. Non-adherence to physical activity is prevalent,
at 21.8 cases per 100 PPY [11, 33, 34]. Exercise interven-
tions showed positive effects on intermediate outcomes,
such as higher aerobic capacity and muscle strength;
however, strong evidences on improved mortality and
graft survival do not exist [34, 35]. One study reported
non-adherence to medical appointments to be low
among KT patients, at 4.7 cases per 100 PPY, with no
association with worse outcomes [11].
Brazil is in a unique position with regard to KT, rank-
ing second worldwide, in the absolute number of KTs
performed and having the largest public transplantation
program. However, regional discrepancies in transplant
activity exist in Brazil, due to differences in regional
population density, human development index, and the
number of transplant services and trained professionals
available. The largest proportion of KT activity is con-
centrated in the South and Southeast regions of the
country and in large transplant centres with high
transplant activity [36–39]. These regional differences,
within the same country and under the same health care
system, provide a valuable opportunity to explore how
differences in service implementation and access to
health services can influence non-adherence after KT.
To date, only a few Brazilian studies have evaluated the
prevalence of non-adherence to immunosuppressive
therapy and health behaviours after KT [20, 40–47].
The ADHERE BRAZIL study aims to explore these
gaps, specifically the prevalence of non-adherence to dif-
ferent health behaviours in the Brazilian KT population,
considering the potential differences in access and chal-
lenges of the Brazilian Health Care System and also per-
forming a broad evaluation of multilevel correlates to
non-adherence to immunosuppressive therapy, including
factors at the level of patients, health care providers,
health care services, and health policies. Involving cen-
tres from all national regions and with different patterns
of transplant activity will provide us with the valuable
opportunity to benchmark patient non-adherence to KT
treatment, characterize differences in patterns of clinical
practice that may be associated with non-adherence, and
a rare opportunity to share experiences among centres.
Methods/Design
The aims of the ADHERE BRAZIL study are as follows:
1. To estimate the prevalence of non-adherence to im-
munosuppressants, and to other treatment-related as-
pects (smoking cessation, alcohol consumption, physical
activity, and appointment keeping), in KT recipients
among different KT centres across different regions of
Brazil; 2. To explore multilevel factors associated to im-
munosuppressive adherence at the level of patient
(socio-demographic, clinical), healthcare provider (pa-
tient satisfaction with the interpersonal dimension of
care, trust in the transplant team, social support), health-
care organization (composition of the team, operational
access, CIM transplant program practice patterns), and
healthcare system and policies (perceived financial bur-
den of the treatment regimen, insurance status, barriers
to access to the immunosuppressive drugs, Brazilian re-
gion); and 3. To benchmark the participating centres, re-
garding their practice patterns that are associated with
non-adherence to health behaviours after KT.
Study design
The ADHERE BRAZIL study is a multicentre, national,
cross-sectional, observational study, based on survey de-
sign. The methodology is derived from the BRIGHT
study [18].
Sampling design and setting
A convenience sample of 20 centres was identified for
inclusion, using a stratified sampling strategy. In Brazil,
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the KT activity of a centre is strongly associated with its
geographical regions and its regional economic develop-
ment. High activity centres are concentrated in the
South and Southeast regions of the country, with low/
moderate activity centres being more prevalent in the
North, Northeast, and Midwest regions. To ensure an
adequate representativeness from the enrolled centres,
we defined four strata of equal size (approximately 283
patients): North, Northeast and Midwest with low or
moderate activity; South and Southeast with low activity;
South and Southeast with moderate activity; and South
and Southeast with high activity. In each stratum, the
number of patients in each centre is proportionally de-
fined by the number of patients being followed up. The
inclusion criteria for centres were as follows: performance
of ≥10 KTs per year over the 5-year period preceding the
study (2010-2014) and a signed agreement provided by
the centre’s director. The 20 centres participating in the
study are listed in Table 1, with their geographical distri-
bution shown in Fig. 2. The majority of centres were lo-
cated along the coast, following the same distribution as
large- and medium-sized Brazilian cities [48].
KT patients are randomly selected using a computer-
generated list (Blockrand package for R language) and
screened according to the following inclusion criteria:
recipient of single and first KT; age > 18 years; > 1-year
post-transplant; and ability to understand the objectives
of the study. Patients are excluded if the immunosup-
pressive regimen is only based on drugs for which the
blood monitoring is not available or not covered by Bra-
zil’s health care system, e.g. mycophenolates without cal-
cineurin or proliferation signal inhibitors. Patients
randomly selected and meeting our inclusion criteria are
invited to participate during their routine medical con-
sultation visits, and those providing written informed
consent are enrolled.
Using the OpenEpi stats program, the sample size was
calculated for studies of population prevalence. Popula-
tion size was defined based on data from the 2012 Bra-
zilian Registry of Transplant (RBT 2012) available
through the Brazilian Association of Transplantation
[49]. Of the 57,815 patients who received a KT in Brazil
from 2000 to 2012, we only considered the 31,241 pa-
tients registered to be under follow up in RBT 2012 as
eligible for our calculation. Based on a non-adherence
prevalence rate of 50%, the 95% confidence interval with
a 5% sample error, and a design effect of 3.0, a sample
size of 1139 patients was calculated and, considering the
multi-stage design of the study, divided into approxi-
mately 283 patients in each stratum.
The number of patients included by each centre, con-
sidered as clusters in the analysis, is proportional to the
number of transplants performed per year and the num-
ber of patients in follow-up, so called the size of the KT
Table 1 Participating centres of the ADHERE BRAZIL Study, divided by Brazilian geographical regions and transplant activity
Centre Brazilian region Transplant activity a
Hospital Ophir Loyola – Belém/PA North Low
Hospital Universitário do Maranhão – São Luiz/MA Northeast Low
Hospital Antônio Targino Ltda. - Campina Grande/PB Northeast Low
Hospital Universitário Onofre Lopes - Natal/RN Northeast Low
Hospital Universitário Walter Cantídio – Fortaleza/CE Northeast Moderate
Hospital Universitário de Brasília – Brasília/DF Midwest Low
Centro Estadual de Transplantes/Hospital São Francisco de Assis na Providência de Deus - Rio de Janeiro/RJ Southeast Moderate
Fundação IMEPEN/Hospital Universitário da Universidade Federal de Juiz de Fora – Juiz de Fora/MG Southeast Low
Fundação Osvaldo Ramos - Hospital do Rim e Hipertensão/UNIFESP – São Paulo/SP Southeast High
Hospital Israelita Albert Einstein – São Paulo/SP Southeast Moderate
Hospital São João de Deus – Divinópolis/MG Southeast Low
Hospital das Clínicas da Universidade Estadual de Campinas/Unicamp – SP Southeast Moderate
Hospital das Clínicas de São Paulo – São Paulo/SP Southeast High
Instituto de Urologia e Nefrologia - Hospital de Base São José Rio Preto – São José do Rio Preto/SP Southeast Low
Santa Casa de Misericórdia de Belo Horizonte – Belo Horizonte/MG Southeast Low
Santa Casa de Misericórdia de Juiz de Fora – Juiz de Fora/MG Southeast Low
Fundação Pró Rim/Hospital Municipal São José – Joinvile/SC South Moderate
Hospital Angelina Caron – Curitiba/PR South Low
Hospital das Clínicas de Porto Alegre – Porto Alegre/RS South High
Santa Casa de Porto Alegre – Porto Alegre/RS South High
a Volume of transplants performed: low activity, < 50 KTs/year; moderate activity, 50 to 150 KTs/year; and high activity ≥150 KTs/year
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centre. According to the RBT 2012, there were 123 ac-
tive transplant centres in Brazil, distributed across 22
states, which performed 5385 KTs in that year [49]. Due
to the absence of an official classification of KT centres
based on their activity, we proposed the following classi-
fication, which is based on a pre-existing classification
for heart transplantation [18], and taking into consider-
ation the profile of the centres included in the study:
low activity, ≤50 KTs/year; moderate activity, 50-150
KTs/year, and high activity, ≥150 KTs/year. We used the
5 years prior to the study period (2010 to 2014) as the
reference period for the KT activity of a centre. Our clas-
sification was validated by consulting specialists through
a web survey, with 92% of respondents considering our
proposal as either ‘adequate’ or ‘very adequate’.
Variables and measurements
The selection of variables was guided by the ecological
model, shown in Fig. 1, which considers the influence of
multiple levels of health care as potential determinants
of a patient’s behaviour [9, 50]. Variables are measured
using established instruments, investigator-developed
measures specific for this study or collected from med-
ical records. A detailed description of the instruments
and operational definitions used are summarized in
Additional file 1: Tables S1 and S2.
Behavioural factors
The implementation phase of medication adherence (tak-
ing and timing dimensions, drug holidays and dose reduc-
tion) [51] to immunosuppressive drugs is measured using
three methods: a validated self-report (Basel Assessment
of Adherence with Immunosuppressive Medication Scale
- BAASIS) [28, 43], blood assay [52], and collateral reports
by health care workers [53]. In addition to the evaluation
provided by each individual method, a composite adher-
ence score is calculated. Overall non-adherence to immu-
nosuppressants will be defined by a positive finding on
any one of the three assessment methods [27, 29]. For
blood assay of immunosuppressants, the actual level and
Fig. 2 Location of centres participating in the study. Transplant activity is indicated in colour, as follows: Red, high activity (> 150 kidney KTs/year);
green, moderate activity (50 to 150 KTs/year); blue, low activity (< 50 KTs/year)
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the levels in the two previous assays are being used [29,
46], as described in Additional file 1: Table S1.
The current physical activity level [54, 55], smoking sta-
tus [18, 56], alcohol use [18, 57], and appointment keeping
[18] are assessed by using investigator-developed ques-
tions based on previous transplant research. These ques-
tions are presented in Additional file 1: Table S1.
Multilevel correlates of non-adherence to immunosuppres-
sive medication
Patient level Demographic (age, sex, race, education,
employment status, marital status, family income), dis-
ease related (aetiology of kidney disease, treatment mo-
dality prior to transplant, preemptive transplant, time on
dialysis, donor type, post-transplant time, comorbidity,
height, weight), and therapy related data (drugs of im-
munosuppressive schema, number of immunosuppres-
sive medications, daily number of doses of
immunosuppressants) are collected through structured
interview and review of charts [20, 26, 58–61]. The fol-
lowing post-transplantation clinical data is collected
from medical charts: number of treated acute rejection
episodes, creatinine level, estimated glomerular filtration
rate, and re-hospitalizations [52, 61–64] (Additional file 1:
Table S2).
Health care provider level (Micro level) A patient’s
trust in the transplant team and satisfaction with his/her
relationship with health care providers are evaluated
using a visual analogue scale (VAS) [65]. Social support
provided to the medication taking is also assessed by
two questions [18] (Additional file 1: Table S2).
Health care organization level (Meso level) With re-
gard to CIM, we include questions on patient-centred
care, continuity and coordination of care, information and
communication technology, organization, and continuous
education provided [18, 66, 67]. Demographic characteris-
tics [20, 67, 68] and satisfaction with operational access to
the transplant centre are also collected [14, 69]. All data
are collected through a self-report questionnaire com-
pleted by a nurse or physician nominated by the trans-
plant centre manager (Additional file 1: Table S2).
Healthcare system and policy level (Macro level) For
KT patients, the Brazilian Public Health System offers
outpatient follow-up, immunosuppressive drugs, labora-
tory exams, and hospitalizations. As the public system is
sometimes inefficient in providing access to the required
exams and to hospitalization, some individuals do
choose to pay for a complimentary private health insur-
ance. Self-reported financial burden is assessed by iden-
tifying the complimentary private health insurance
status [20]. City and region specific data related to
health care access, such as number of hospitals and the
number of intensive care beds available, and relevant in-
formation about the transplant centre are retrieved from
the 2012 RBT [49], as summarized in Additional file 1:
Table S2.
Recruitment/data collection
Recruitment and data collection are centrally managed
by the coordinator centre, the Federal University of Juiz
de Fora, Juiz de Fora. After obtaining approval of the
project by the ethics research board (ERB) of the coord-
inating centre, all invited centres submitted the project
to their local ERB. All data collection is performed using
the Research Electronic Data Capture (RedCap) system.
Local research coordinators receive a detailed step-by-
step training guide, followed by a specific training ses-
sion via phone or podcast. Backup support for data col-
lection is continuously available through the ADHERE
BRAZIL study via phone, e-mail, or Skype. Once the
project is locally approved by ERB and the local research
team has been trained, the access to RedCap system is
provided through a unique identification and password.
This allows the centre to update and visualize only its
data. The RedCap system is a safe internet program, cre-
ated by Vanderbilt University, designed exclusively for
the capture and storage of data that can accessed re-
motely by trained individuals. RedCap allows data to be
collected, organized, and stored in an integrated manner,
making the process of data analysis less time-consuming
and feasible across multiple centres. Furthermore, users
can access their database at any time to complete or up-
date their data over the collecting time (http://www.pro-
ject-redcap.org/).
Patient data collection
Data will be collected over an 18-month period, during
regular medical visits to the transplant service and dir-
ectly entered into the RedCap database by a trained pro-
fessional. Scheduled patients are randomly selected
using routine computerized method. Eligible patients,
randomly selected by a list generated with the blockrand
package for R language, are invited to participate and to
sign the informed consent. Then, the BAASIS interview
[28, 43] and the structured questionnaire are applied.
The collateral report is completed by the physician/
nurse on the same day. Blood levels of immunosuppres-
sive drugs and other clinical variables are extracted from
the medical records.
Transplant centre’s data collection
A representative of the transplant service, indicated by
the centre’s manager, enters the data from the question-
naire directly into Red Cap system.
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Data collection began on December 7, 2015, and is
planned for 18 months, with expected completion in
June 2017. The quality of the information registered into
the RedCap system of each centre is verified by the cen-
tral study coordinators on a weekly basis, ensuring that
there is no missing data or errors in data entry, and re-
ports of found inadequacies are regularly, once a week,
reported to each centre. Once data collection is com-
pleted, a summary report of adherence rates and factors
associated with non-adherence will be provided to each
centre. After completion of the study, a benchmark re-
port will be sent to each transplant centre, in which the
results of each will be summarized and compared to the
data from other centres. Only the information of the
centre receiving the report will be individualized, with
the data from other centres presented in pooled and
anonymized manner.
Statistical analysis plan
Aim 1
In addition to the general prevalence estimates of non-
adherence to health behaviours, the adopted sample de-
sign allows for stratified estimates to be calculated ac-
cording to region (South/Southeast, North/Midwest/
Northeast), the activity level of the transplant centre,
and the sample strata. Prevalence estimates will be pre-
sented as percentages, with their respective 95% confi-
dence intervals (95% CI), calculated using Taylors’
Linearization Series given the multistage sampling de-
sign of the study. For numerical variables with a normal
distribution, the mean and respective 95% CI will be cal-
culated and for variables with significantly skewed distri-
bution, the median and inter-quartile interval. Box-plots
and normal probability plots will be used to assess the
distribution properties. Graphics will be used, where
relevant, to enhance visualization, including grouped
box-plots and bar plots for prevalence.
Aim 2
To explore the association between medication non-
adherence and multilevel studied correlates, the analyses
will follow the multilevel ecological model, following the
hierarchical approach [70]. This approach is a forward
driven variable selection method, based on the epi-
demiological framework adopted, following the proxim-
ity of the variable levels to the patient in a theoretical
causal framework. The non-adherence indicator (binary)
variable will be analysed using generalized estimation
equations (GEE). This population average approach is an
adequate modelling framework that can handle the
multistage nature of the study design, as well as provides
flexibility regarding the probability distribution adequate
to each outcome variable nature, and consequently the
association parameter to be estimated. For instance,
binary outcomes, such as non-adherence, will be mod-
elled using the Poisson distribution and the log link
function, providing prevalence ratios as association par-
ameter. Discrete or count outcomes, like absence at
scheduled follow-up consultations, can also be modelled
as a Poisson or Negative Binomial distribution with log
link function, but providing a counting rate ratios as the
association parameter. Association effects will be consid-
ered of scientific relevance on the basis on their magni-
tude (effect size), precision (by their 95% CI) and
associated p-value. As per the recent statement from the
American Statistical Association, terms such as ‘statisti-
cally significant and model adjustment based only on p-
values’ will no longer be adopted in the analysis [71].
All analyses will be performed using IBM Statistics
(SPSS 24.0, Chicago, IL, USA) and STATA (version 14,
StataCorp LP, College Station, TX, USA) statistical pack-
ages. All codes used will be publically available, permit-
ting reproducibility.
Ethical considerations
The study was reviewed and approved by the ERB of
University Hospital of Federal University of Juiz de Fora
(691.120), and nationally registered (CAAE
27972914.1.1001.5133). All participating centres also lo-
cally submitted the protocol to ERB approval before data
collection. Information and informed consent followed
the guidelines of the Declaration of Helsinki (World
Medical Organization 1996) and specific national legisla-
tions. Written informed consent will be obtained from
all the participants before the data collection.
Discussion
By using appropriate methodology, our study will pro-
vide a broad and more representative information re-
garding non-adherence among KT patients in Brazil.
Furthermore, we will also identify factors associated with
medication adherence, especially at the level of health
care service and health care team, which could provide
potential leverage points for developing further interven-
tions. This is the first multi-centre study that is assessing
adherence and multilevel correlates in KT patients and
in Brazil, which has a universal and public health care
system and a territorial varsity. The social and economic
diversity across the country, which mirrors the variation
in the availability and access to health care, offers a
unique opportunity to explore non-adherence. It is one
of the few studies assessing patient non-adherence to
the different aspects of the post-KT treatment, includ-
ing: medication intake, alcohol and smoking cessation,
physical activity and appointment keeping in a large KT
population.
The use of a consistent methodology of non-
adherence to medication measurements will provide an
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accurate prevalence and allow us to conduct reliable
comparisons between centres, regions, and clinical prac-
tice patterns. Our sampling methodology tried to avoid
selection bias of patients, given that the centres were se-
lected by convenience. Recruiting centres from all re-
gions, and then including different patterns of clinical
practice, administration and transplant activity, and a
randomized selection of patients, will increase the reli-
ability of the study findings to Brazil and to other coun-
tries with similar health systems. The multilevel analysis
of factors associated with non-adherence, including at
the level of the patient, healthcare provider, health care
organization, health care system and policies, will enable
us to capture a wide range of factors correlated to non-
adherence. Furthermore, we believe that the identifica-
tion of the clinical practice patterns positively associated
with adherence might be the most valuable potential
contribution of this study, and such practices can be
promptly adopted in KT care. This information, for the
first time involving a large sample of KT patients, will
provide an accurate view of the current state of non-
adherence after KT, and identify targets for further inter-
ventions. Data collection using the RedCap system pro-
motes a constant and ongoing quality surveillance of
included data. The RedCap system provides a useful tool
for collecting data across multiple centres and for prob-
lem solving, at a distance, which is essential considering
that our study covers a territory of 328,804 mi2 and 200
million inhabitants. As another relevant point, we will
provide feedback to each centre regarding their patients’
adherence behaviours, which the centres can use to im-
prove their clinical practice.
Our study has certain limitations. First, although the
20 centres included in the study were representative of
different kinds of centres and regions of Brazil, these
centres were selected and recruited by convenience,
which allowed our study to be economically feasible and
to achieve a potential low dropout rate. Although cen-
tres were selected by convenience, patients were ran-
domly selected. Second, due to limited resources, it was
not possible to evaluate non-adherence to immunosup-
pressants using electronic monitoring. We opted to
apply a combination of diagnostic methods [27], (i.e. pa-
tient self-report, collateral report from nurse/physician,
and immunosuppressive blood levels) which has previ-
ously been shown to provide the highest sensitivity com-
pared to electronic monitoring [29]. Our evaluation of
the CIM model is limited but, to our knowledge, this
will be the first time that this model is being evaluated
within the context of KT. Finally, as a cross-sectional
study, causality between identified factors and non-
adherence to post-KT treatment cannot be inferred.
In conclusion, the ADHERE Brazil study is a cross-
sectional study evaluating various aspects of non-
adherence behaviour to the treatment regimen, and
multi-level correlates to immunosuppressive medication
non-adherence in 1130 patients across 20 KT centres.
Data from this study will provide evidence to people in-
volved in treating KT patients (health care professionals,
health care policy makers) regarding the level (patient,
health care professional, and health care system and pol-
icies) at which further interventions should be imple-
mented to improve adherence to the post-KT treatment
and, consequently, the long-term outcomes.
Additional file
Additional file 1: Table S1. Behavioural factors. Table S2. Multilevel
correlates of nonadherence to immunosuppressants. (DOCX 50 kb)
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